Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India
|
EQS-News: Olympus Corp.
/ Key word(s): Miscellaneous
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India Endoscopy Engineering support services in India
Tokyo, Japan, 12 June 2024, JCN Newswire - Olympus Corporation (Olympus), a global MedTech Company committed to making people’s lives healthier, safer and more fulfilling, today announced its strategic initiative to establish an R&D Offshore Development Center (ODC) in Hyderabad, India. This decision comes as a result of a strategic agreement with global technology company HCLTech, aimed at diversifying Olympus' innovation generation activities. Establishing this R&D ODC in Hyderabad is part of Olympus' commitment to leverag e global R&D talents and resources driving advancements in medical technology. Hyderabad is a major metropolitan area and is known as India’s MedTech hub, providing the talent needed for research and development activities necessary for Olympus' expansion efforts. Concurrent with the creation of the ODC, Olympus will also prepare for the establishment of Olympus’ in-house R&D center in the coming years. This center would be in addition to the company’s current R&D centers in Japan, the United States, and Europe. The company plans to further establish its presence in the country by collaborating with AIG Hospitals, Hyderabad for joint research projects. By partnering with one of India's premier healthcare institutions, Olympus aims to leverage clinical expertise and insights to drive t he development of innovative medical solutions that address the evolving needs of patients worldwide. Since establishing Olympus Medical Systems India Private Limited in 2009, Olympus has continued to expand its operations in India and has achieved growth with the support of its many stakeholders. These strategic initiatives not only reinforce Olympus’ commitment to advancing medical technology but also strengthen its global footprint and enhance the company’s ability to deliver impactful healthcare solutions.
Comment from Andre Roggan, Chief Technology Officer at Olympus “It is with great pleasure and excitement that we announce this agreement with HCLTech, with whom we share a decade-long partnership in core engineering and R&D services. I am confident that our collaboration will enhance Olympus’ engineering capabilities and unlock new innovations that enable quality healthcare through technology.”
Comment from Mr. D. Sridhar Babu, Minister of Information Technology, Electronics & Communications (ITE&C) and Industries & Commerce (I&C) of the Government of Telangana “We are thrilled that Olympus Corporation, one of the world's largest medical device companies, has chosen Hyderabad for its first investment in India with an R&D center, marking a significant milestone for our city's medical devices ecosystem. With Hyderabad's robust infrastructure, strategic location, and thriving community of innovative healthcare companies, this investment is poised to be a game-changer for the medical devices sector in India. We are confident that Olympus' advanced technologies and expertise will significantly contribute to our vision of becoming a global hub for medical device innovation and manufacturing. I welcome Olympus Corporation to our ecosystem.”
About HCLTech HCLTech is a global technology company, home to more than 227,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud , and AI, powered by a broad portfolio of technology services and products. HCLTech works with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG, and Public Services. Consolidated revenues as of the 12 months ending March 2024 totalled $13.3 billion. To learn how HCLTech can supercharge progress for you, visit hcltech.com.
About Olympus At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit olympus-global.com and follow our global X account: @Olympus_Corp.
Media contact: Mail: Global-Public_Relations@olympus.com
Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com
12.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
1923725 12.06.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.